Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 5.1.99.4 - alpha-methylacyl-CoA racemase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
25/26-hydroxycholesterol 7alpha-hydroxylase deficiency
Mechanisms of disease: Inborn errors of bile acid synthesis.
Acquired Immunodeficiency Syndrome
Alpha-methylacyl-CoA-racemase expression in adenocarcinoma, dysplasia and non-neoplastic epithelium of the stomach.
Microcystic adenocarcinoma of the prostate: a variant of pseudohyperplastic and atrophic patterns.
Adenocarcinoma
34BetaE12 and Alfa-Methylacyl Coenzyme A Racemase (AMACR) Antibodies Better Than p63 Antibody Distinguish Normal and Neoplastic Glands in Prostatic Tissue With Thermal Artifacts.
?-Methylacyl-CoA Racemase (AMACR) in Gastric Cancer: Correlation With Clinicopathologic Data and Disease-free Survival.
A cross sectional study of p504s, CD133, and Twist expression in the esophageal metaplasia dysplasia adenocarcinoma sequence.
A Novel Monoclonal Antibody Against Alpha-Methylacyl-CoA Racemase Applicable for Paraffin-Embedded Tissues and Diagnostics of Prostate Cancer.
a-Methylacyl coenzyme A racemase is highly expressed in the intestinal-type adenocarcinoma and high-grade dysplasia lesions of the stomach.
Abundant expression of AMACR in many distinct tumour types.
Alpha methylacyl-CoA racemase (AMACR) in prostate adenocarcinomas from Japanese patients: Is AMACR a "race"-dependent marker?
Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
Alpha-methylacyl coenzyme A racemase immunoreactivity in partial atrophy of the prostate.
Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Alpha-Methylacyl-CoA Racemase Expression is Upregulated in Gastric Adenocarcinoma: A Study of 249 Cases.
Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker.
Alpha-methylacyl-CoA-racemase expression in adenocarcinoma, dysplasia and non-neoplastic epithelium of the stomach.
Alpha-methylacyl-coenzyme A racemase expression in neuroendocrine neoplasms of the stomach.
Altered expression of alpha-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy.
AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
AMACR is highly expressed in gastric adenomas and intestinal-type carcinomas.
Ancillary alpha-methylacyl-CoA racemase immunocytochemistry in the diagnosis of adenocarcinoma of the prostate in urinary cytology: a case report.
Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review.
Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Cancer of unknown primary finally revealed to be a metastatic prostate cancer: a case report.
CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma.
Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S.
Clinical significance of the expression of alpha-methylacyl-CoA racemase in squamous cell carcinoma and adenocarcinoma of the lung.
Cytokeratin (AE1/AE3) in addition to alpha-methylacyl coenzyme A racemase (P504S), 34-beta-E12, and p63 stains in evaluation of surgical specimens after hormonal therapy for prostatic adenocarcinoma.
Detection of alpha-methylacyl-coenzyme A racemase in postradiation prostatic adenocarcinoma.
Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy.
Diagnosis of adenocarcinoma in prostate needle biopsy tissue.
Diagnostic utility of a-methylacyl COA racemase in prostate cancer of the Iranian population.
Differential expression of alpha-methylacyl coenzyme A racemase in adenocarcinomas of the small and large intestines.
Expression of Alpha - Methylacyl - Coenzyme A Racemase (AMACR) in Colorectal Neoplasia.
Expression of Alpha Methylacyl CoA Racemase (AMACR) in Gastric Adenocarcinoma and Its Correlation with Helicobacter pylori Infection.
Expression of alpha-methylacyl coenzyme A racemase in partial and complete focal atrophy on prostate needle biopsies.
Expression of alpha-methylacyl coenzyme A racemase in the dysplasia carcinoma sequence associated with Barrett's esophagus.
Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate.
Expression of alpha-methylacyl-CoA racemase (P504S) in nephrogenic adenoma: a significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma.
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Expression of alpha-methylacyl-CoA racemase in vaginal gastric-type adenocarcinoma and uterine clear cell carcinoma.
Expression of alpha-methylacyl-coenzyme A racemase in dysplastic Barrett's epithelium.
Expression of alpha-methylacyl-coenzyme A racemase in nephrogenic adenoma.
High-Throughput Screen Identifies Novel Inhibitors of Cancer Biomarker {alpha}-Methylacyl Coenzyme A Racemase (AMACR/P504S).
Human telomerase and alpha-methylacyl-coenzyme A racemase in prostatic carcinoma. A comparative immunohistochemical study.
Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Immunohistochemical Staining Characteristics of Nephrogenic Adenoma Using the PIN-4 Cocktail (p63, AMACR, and CK903) and GATA-3.
Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update.
Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver.
IMP3 Immunoreactivity is More Sensitive Than AMACR in Detecting Dysplastic Epithelium and Early Adenocarcinoma in Barrett Esophagus.
Intestinal, intestinal-type and intestine-localized metastatic adenocarcinoma. Immunohistochemical approach to the differential diagnosis.
Is atypical adenomatous hyperplasia of the prostate a precursor lesion?
Is there a role for fatty acid synthase in the diagnosis of prostatic adenocarcinoma?: A comparison with AMACR.
MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma: ?A Comparison With AMACR.
Microcystic adenocarcinoma of the prostate: a variant of pseudohyperplastic and atrophic patterns.
Modeling African American prostate adenocarcinoma by inducing defined genetic alterations in organoids.
Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma.
Overlapping Immunohistochemical Features of Adenocarcinoma of the Nonpigmented Ciliary Body Epithelium and Renal Cell Carcinoma.
P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies.
P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy.
Performance comparison of anti-p504s (SP116) Rabbit Monoclonal Primary Antibody vs. Monoclonal Rabbit Anti-Human AMACR clone 13H4 when duplexed with VENTANA Basal Cell Cocktail (34?E12+p63) as a diagnostic aid for prostatic adenocarcinoma using immunohistochemistry.
Primary prostate cancer synchronous with renal cell carcinoma: clinical experience and literature review.
Primary seminal vesicle adenocarcinoma: A case report of rare entity and discussion of its differential diagnosis using immunohistochemical approach for the core biopsy specimen.
Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein.
Prostatic adenocarcinoma oncocytic variant: Case report and literature review.
Relationship between alpha-methylacyl-coenzyme A racemase expression and mucin phenotype in gastric cancer.
Reliability of the 34betaE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma.
Routine immunohistochemical staining for high-molecular weight cytokeratin 34-beta and alpha-methylacyl CoA racemase (P504S) in postirradiation prostate biopsies.
S-100A1 Is a Reliable Marker in Distinguishing Nephrogenic Adenoma From Prostatic Adenocarcinoma.
Sensitivity of P504S/alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry for the detection of prostate carcinoma on stored needle biopsies.
Significance of overexpression of alpha methylacyl-coenzyme A racemase in hepatocellular carcinoma.
Significance of prostate cancer missed on needle biopsy tools for retrieving missed cancer.
Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia.
The expressions of AMACR and iNOS in prostate adenocarcinomas.
The significance of the P504S expression pattern of high-grade prostatic intraepithelial neoplasia (HGPIN) with and without adenocarcinoma of the prostate in biopsy and radical prostatectomy specimens.
Urothelial-type adenocarcinoma of the prostate mimicking metastatic colorectal adenocarcinoma.
Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens.
Utility of ERG Versus AMACR Expression in Diagnosis of Minimal Adenocarcinoma of the Prostate in Needle Biopsy Tissue.
Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.
Variation of alpha-methylacyl-CoA racemase expression in prostate adenocarcinoma cases receiving hormonal therapy.
What's new in prostate cancer disease assessment in 2006?
[Achievements in morphological diagnosis of prostatic cancer: alpha-methylacyl-coenzyme-A-racemase--a new marker of malignant cell transformation]
[Assessment of P504S immunohistochemistry in diagnosis and differential diagnosis of prostatic adenocarcinoma.]
[Detection of P504S (alpha-methylacyl-CoA racemase) in prostatic adenocarcinomas]
[Estimation of the diagnostic potential of APOD, PTOV1, and EPHA4 for prostatic neoplasms].
[Fatty acid synthase in the diagnosis of prostate neoplasms].
[Histopathological features of prostate cancer]
[Small suggestive lesions of the prostate Histological and immunohistochemical analyses -- report of the uropathology consultation service]
Adenocarcinoma of Lung
Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver.
Adenocarcinoma, Clear Cell
Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S.
Adenoma
A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma.
Abundant expression of AMACR in many distinct tumour types.
Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma.
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
AMACR is associated with advanced pathologic risk factors in sporadic colorectal adenomas.
AMACR is highly expressed in gastric adenomas and intestinal-type carcinomas.
AMACR Positive Papillary Renal Adenomatosis and Multifocal Papillary Carcinoma in End Stage Renal Disease.
Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S.
Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon.
Differential expression of p53 and p504s in hyperplastic polyp, sessile serrated adenoma and traditional serrated adenoma.
Distal Tubular Hyperplasia: A Proposal for a Unique Form of Renal Tubular Proliferation Distinct From Papillary Adenoma.
Expression of Alpha - Methylacyl - Coenzyme A Racemase (AMACR) in Colorectal Neoplasia.
Expression of alpha-methylacyl-CoA racemase (P504S) in nephrogenic adenoma: a significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma.
Expression of alpha-methylacyl-CoA racemase (P504S) in sebaceous neoplasms.
Expression of alpha-methylacyl-coenzyme A racemase in nephrogenic adenoma.
Flat pattern of nephrogenic adenoma: previously unrecognized pattern unveiled using PAX2 and PAX8 immunohistochemistry.
Immunohistochemical Staining Characteristics of Nephrogenic Adenoma Using the PIN-4 Cocktail (p63, AMACR, and CK903) and GATA-3.
Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma.
Nephrogenic adenoma of the urinary tract: clinical, histological, and immunohistochemical characteristics.
Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma.
Nephrogenic adenomas in pediatric patients: a morphologic and immunohistochemical study of 21 cases.
Renal papillary adenoma--a putative precursor of papillary renal cell carcinoma.
S-100A1 Is a Reliable Marker in Distinguishing Nephrogenic Adenoma From Prostatic Adenocarcinoma.
Variants in the alpha-Methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma.
Adenoma, Liver Cell
Significance of overexpression of alpha methylacyl-coenzyme A racemase in hepatocellular carcinoma.
Adenoma, Oxyphilic
Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study.
Immunohistochemical detection of P504S in primary and metastatic renal cell carcinomas.
Papillary renal cell carcinoma embedded in an oncocytoma: Case report of a rare combined tumour of the kidney.
Adenoma, Villous
AMACR is associated with advanced pathologic risk factors in sporadic colorectal adenomas.
Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon.
Adenomatous Polyposis Coli
Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
Adrenoleukodystrophy
Clinical consequences of defects in peroxisomal beta-oxidation.
Albinism, Oculocutaneous
Incidental finding of alpha-methylacyl-CoA racemase deficiency in a patient with oculocutaneous albinism type 4.
alpha-methylacyl-coa racemase deficiency
A mouse model for alpha-methylacyl-CoA racemase deficiency: adjustment of bile acid synthesis and intolerance to dietary methyl-branched lipids.
Alpha methyl acyl CoA racemase deficiency: Diagnosis with isolated elevated liver enzymes.
An adult onset case of alpha-methyl-acyl-CoA racemase deficiency.
Asymptomatic retinal dysfunction in alpha-methylacyl-CoA racemase deficiency.
Clinical consequences of defects in peroxisomal beta-oxidation.
Episodic hyperCKaemia may be a feature of ?-methylacyl-coenzyme A racemase deficiency.
Fibroblast studies documenting a case of peroxisomal 2-methylacyl-CoA racemase deficiency: possible link between racemase deficiency and malabsorption and vitamin K deficiency.
Incidental finding of alpha-methylacyl-CoA racemase deficiency in a patient with oculocutaneous albinism type 4.
Mechanisms of disease: Inborn errors of bile acid synthesis.
MRI characterisation of adult onset alpha-methylacyl-coA racemase deficiency diagnosed by exome sequencing.
Phytol is lethal for Amacr-deficient mice.
Plasma analysis of di- and trihydroxycholestanoic acid diastereoisomers in peroxisomal alpha-methylacyl-CoA racemase deficiency.
Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation.
Reinvestigation of peroxisomal 3-ketoacyl-CoA thiolase deficiency: identification of the true defect at the level of d-bifunctional protein.
Relapsing encephalopathy in a patient with alpha-methylacyl-CoA racemase deficiency.
Relapsing rhabdomyolysis due to peroxisomal alpha-methylacyl-coa racemase deficiency.
Stereochemistry of the peroxisomal branched-chain fatty acid alpha- and beta-oxidation systems in patients suffering from different peroxisomal disorders.
Subcellular localization and physiological role of alpha-methylacyl-CoA racemase.
The influence of the branched-chain fatty acids pristanic acid and Refsum disease-associated phytanic acid on mitochondrial functions and calcium regulation of hippocampal neurons, astrocytes, and oligodendrocytes.
Tremor and deep white matter changes in alpha-methylacyl-CoA racemase deficiency.
Angiomyolipoma
Alpha-methyl CoA racemase expression in renal cell carcinomas.
Arthritis
Impaired intrinsic chiral inversion activity of ibuprofen in rats with adjuvant-induced arthritis.
Barrett Esophagus
A cross sectional study of p504s, CD133, and Twist expression in the esophageal metaplasia dysplasia adenocarcinoma sequence.
AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
Expression of alpha-methylacyl coenzyme A racemase in the dysplasia carcinoma sequence associated with Barrett's esophagus.
IMP3 Immunoreactivity is More Sensitive Than AMACR in Detecting Dysplastic Epithelium and Early Adenocarcinoma in Barrett Esophagus.
p16, Cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus.
Brain Diseases
Phytol is lethal for Amacr-deficient mice.
Relapsing encephalopathy in a patient with alpha-methylacyl-CoA racemase deficiency.
Brain Neoplasms
Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma.
Breast Diseases
[Antigen retrieval immunohistochemistry under the influence of pH value and time]
Breast Neoplasms
Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis.
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer.
Carcinogenesis
A statistical method for identifying differential gene-gene co-expression patterns.
a-Methylacyl coenzyme A racemase is highly expressed in the intestinal-type adenocarcinoma and high-grade dysplasia lesions of the stomach.
Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer.
Alpha-methylacyl-CoA-racemase expression in adenocarcinoma, dysplasia and non-neoplastic epithelium of the stomach.
Chromosome 5p Region SNPs Are Associated with Risk of NSCLC among Women.
Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon.
Diagnostic roles of proliferative markers in pathological Grade of T1 Urothelial Bladder Cancer.
Differential expression of alpha-methylacyl coenzyme A racemase in adenocarcinomas of the small and large intestines.
Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance.
Expression of Alpha - Methylacyl - Coenzyme A Racemase (AMACR) in Colorectal Neoplasia.
High frequency of the SDK1:AMACR fusion transcript in Chinese prostate cancer.
Human prostate cancer precursors and pathobiology.
Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk.
Transcriptome analysis of human colon Caco-2 cells exposed to sulforaphane.
Variants in the alpha-Methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma.
Carcinoid Tumor
Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
Carcinoma
?-Methylacyl-CoA racemase (P504S) is a useful marker for the differential diagnosis of solid pseudopapillary neoplasm of the pancreas.
?-Methylacyl-CoA racemase: a useful immunohistochemical marker of breast carcinoma with apocrine differentiation.
A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma.
A renal cell carcinoma with components of both chromophobe and papillary carcinoma.
a-Methylacyl coenzyme A racemase is highly expressed in the intestinal-type adenocarcinoma and high-grade dysplasia lesions of the stomach.
Abundant expression of AMACR in many distinct tumour types.
Adult Nephroblastoma with Predominant Epithelial Component: A Differential Diagnostic Candidate of Papillary Renal Cell Carcinoma and Metanephric Adenoma-Report of Three Cases.
Adult papillary renal tumor with oncocytic cells: clinicopathologic, immunohistochemical, and cytogenetic features of 10 cases.
Age-associated changes in alpha-methyl CoA racemase (AMACR) expression in nonneoplastic prostatic tissues.
Alpha-methyl CoA racemase expression in renal cell carcinomas.
Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
Alpha-methylacyl coenzyme A racemase immunoreactivity in partial atrophy of the prostate.
alpha-methylacyl coenzyme A racemase is immunoreactive in extramammary Paget disease.
Alpha-methylacyl coenzyme A racemase overexpression in gallbladder carcinoma confers an independent prognostic indicator.
alpha-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer.
Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer.
Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer.
Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression.
Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone.
Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma.
Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis.
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
Alpha-methylacyl-CoA-racemase expression in adenocarcinoma, dysplasia and non-neoplastic epithelium of the stomach.
Altered expression of alpha-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy.
AMACR is highly expressed in gastric adenomas and intestinal-type carcinomas.
AMACR overexpression acts as a negative prognostic factor in oral squamous cell carcinoma.
AMACR overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma.
AMACR Positive Papillary Renal Adenomatosis and Multifocal Papillary Carcinoma in End Stage Renal Disease.
Atypical Renal Cysts: A Morphologic, Immunohistochemical, and Molecular Study.
Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Can p503s, p504s and p510s gene expression in peripheral-blood be useful as a marker of prostatic cancer?
CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia.
Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S.
Clear cell papillary renal cell carcinoma: a case report and literature review.
Clear Cell Renal Cell Carcinoma Metastatic to the Gynecologic Tract: A Clinicopathologic Analysis of 17 Cases.
Clear Cell Renal Cell Carcinoma With Borderline Features of Clear Cell Papillary Renal Cell Carcinoma: Combined Morphologic, Immunohistochemical, and Cytogenetic Analysis.
Clinical significance of the expression of alpha-methylacyl-CoA racemase in squamous cell carcinoma and adenocarcinoma of the lung.
Collecting duct carcinoma of the kidney: an immunohistochemical evaluation of the use of antibodies for differential diagnosis.
Comparative analysis of Napsin A, alpha-methylacyl-coenzyme A racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumours.
Comparative analysis of three- and two-antibody cocktails to AMACR and basal cell markers for the immunohistochemical diagnosis of prostate carcinoma.
Correlation of cyclin D1, HER2, and AMACR expressions with histologic grade in bladder urothelial carcinomas.
Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon.
Detection of alpha-methylacyl-coenzyme A racemase in postradiation prostatic adenocarcinoma.
Detection of prostate cancer by alpha-methylacyl CoA racemase (P504S) in needle biopsy specimens previously reported as negative for malignancy.
Diagnostic utility of a p63/alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate.
Diagnostic utility of alpha-methylacyl CoA racemase (P504S) on prostate needle biopsy.
Diagnostic utility of P504S/p63 cocktail, prostate-specific antigen, and prostatic acid phosphatase in verifying prostatic carcinoma involvement in seminal vesicles: a study of 57 cases of radical prostatectomy specimens of pathologic stage pT3b.
Diagnostic utility of triple antibody (AMACR, HMWCK and P63) stain in prostate neoplasm.
Diagnostic Value of Cytokeratin 34 beta E12 (Ck34?E12) and ?-Methylacyl-CoA racemase (AMACR) Immunohistochemical Expression in Prostatic Lesions.
Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance.
Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S).
Do Clear Cell Papillary Renal Cell Carcinomas Have Malignant Potential?
Do clear cell papillary renal cell carcinomas have malignant potential? Diolombi ML, Cheng L, Argani P, Epstein JI.Am J Surg Pathol. December 2015;39(12):1621-1634.
Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ?
Endometrial Tumor Classification by Histomorphology and Biomarkers in the Nurses' Health Study.
Evaluation of role of alpha-methyl acyl-coenzyme A racemase/P504S and high molecular weight cytokeratin in diagnosing prostatic lesions.
Expression of Alpha - Methylacyl - Coenzyme A Racemase (AMACR) in Colorectal Neoplasia.
Expression of alpha-methylacyl coenzyme A racemase in the dysplasia carcinoma sequence associated with Barrett's esophagus.
Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate.
Expression of alpha-methylacyl-CoA racemase (P504S) in sebaceous neoplasms.
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Expression of alpha-methylacyl-CoA racemase correlates with histopathologic grading in noninvasive bladder cancer.
Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma.
Expression of alpha-methylacyl-CoA racemase in vaginal gastric-type adenocarcinoma and uterine clear cell carcinoma.
Foamy gland carcinoma in core needle biopsies of the prostate: clinicopathologic and immunohistochemical study of 56 cases.
Foamy Gland Carcinoma of the Prostate in Needle Biopsy: Incidence, Gleason Grade, and Comparative ?-Methylacyl-CoA Racemase vs. ERG Expression.
GATA-3 Expression in all Grades and Different Variants of Primary and Metastatic Urothelial Carcinoma.
Gene expression profiling of clear cell papillary renal cell carcinoma: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.
Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.
High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.
Human telomerase and alpha-methylacyl-coenzyme A racemase in prostatic carcinoma. A comparative immunohistochemical study.
Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: significant immunophenotypic overlap warrants diagnostic caution.
Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy.
Immunohistochemical detection of P504S in primary and metastatic renal cell carcinomas.
Immunohistochemical phenotype and molecular pathological characteristics of metanephric adenoma.
Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues.
Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update.
In situ and intraductal epithelial proliferations of prostate: definitions and treatment implications. Part 1: Prostatic intraepithelial neoplasia.
Is there a role for fatty acid synthase in the diagnosis of prostatic adenocarcinoma?: A comparison with AMACR.
Is there a role for prostate tumour overexpressed-1 in the diagnosis of HGPIN and of prostatic adenocarcinoma? A comparison with alpha-methylacyl CoA racemase.
Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Lymphoepithelioma-like carcinoma of the prostate.
Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer.
Napsin-A and AMACR are Superior to HNF-1? in Distinguishing Between Mesonephric Carcinomas and Clear Cell Carcinomas of the Gynecologic Tract.
Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma.
p16 Expression in Prostate Cancer and Nonmalignant Lesions: Novel Findings and Review of the Literature.
P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies.
P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy.
P504S: a new molecular marker for the detection of prostate carcinoma.
Papillary renal cell carcinoma with diffuse clear cells and thyroid-like macrofollicular areas.
Phase-Regulated Sensing Mechanism of MoS2 Based Nanohybrids toward Point-of-Care Prostate Cancer Diagnosis.
Preparation and characterization of the antibody recognizing AMACR inside its catalytic center.
Profiling and classification tree applied to renal epithelial tumours.
Prognostic Significance of alpha-Methylacyl-CoA Racemase Among Men With High Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsies.
Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma.
Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens.
Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
Recent advances of immunohistochemistry for diagnosis of renal tumors.
Relationship between alpha-methylacyl-coenzyme A racemase expression and mucin phenotype in gastric cancer.
Reliability of the 34betaE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma.
Renal cell carcinoma with mixed features of papillary and clear cell cytomorphology: a fluorescent in situ hybridization study.
Renal cell carcinomas with papillary architecture and clear cell components: the utility of immunohistochemical and cytogenetical analyses in differential diagnosis.
Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature.
Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study.
Routine immunohistochemical staining for high-molecular weight cytokeratin 34-beta and alpha-methylacyl CoA racemase (P504S) in postirradiation prostate biopsies.
Sensitivity of P504S/alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry for the detection of prostate carcinoma on stored needle biopsies.
Serum total prostate-specific antigen (tPSA): correlation with diagnosis and grading of prostate cancer in core needle biopsy.
The significance of the P504S expression pattern of high-grade prostatic intraepithelial neoplasia (HGPIN) with and without adenocarcinoma of the prostate in biopsy and radical prostatectomy specimens.
The utility of alpha-methyl CoA racemase (P504S) expression as a marker of renal cell carcinomas.
Tubulocystic renal cell carcinoma with poorly differentiated foci is indicative of aggressive behavior: clinicopathologic study of two cases and review of the literature.
Tubulocystic renal cell carcinoma: Report of a rare case.
Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
Use of p63/P504S monoclonal antibody cocktail in immunohistochemical staining of prostate tissue.
Useful immunohistochemical panel for differentiating clear cell papillary renal cell carcinoma from its mimics.
Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens.
Utility of ?-methylacyl-coenzyme-A racemase (p504s) immunohistochemistry in distinguishing endometrial clear cell carcinomas from serous and endometrioid carcinomas.
Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer.
Utility of immunohistochemistry markers in the interpretation of post-high-intensive focussed ultrasound prostate biopsy cores.
Utility of racemase and other immunomarkers in the detection of adenocarcinoma in prostatic tissue damaged by high intensity focused ultrasound therapy.
Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.
[Achievements in morphological diagnosis of prostatic cancer: alpha-methylacyl-coenzyme-A-racemase--a new marker of malignant cell transformation]
[Alpha-methylacyl-CoA racemase: a useful marker for diagnosis of prostatic carcinoma.]
[Antigen retrieval immunohistochemistry under the influence of pH value and time]
[Diagnostic utility of immunohistochemistry in differential diagnosis of renal tumors with oncocytic features].
[Expression of cadherin17 in metanephric adenoma and its value in differential diagnosis].
[Gleason histologic grading of prostate carcinoma in relation to serum PSA, PSA in situ and immunohistochemical expression of 34 beta E12 and P504S]
[Metastatic renal cell carcinoma: a clinicopathological analysis of 196 cases].
[Sensitivity and specificity of AMACR expression in diagnosis of prostatic carcinoma]
[Small suggestive lesions of the prostate Histological and immunohistochemical analyses -- report of the uropathology consultation service]
[The value of alpha-methylacyl-CoA racemase expression in the progression of colonic carcinoma].
[Tubulocystic carcinoma of the kidney].
Carcinoma in Situ
CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia.
Carcinoma, Acinar Cell
?-Methylacyl-CoA racemase (P504S) is a useful marker for the differential diagnosis of solid pseudopapillary neoplasm of the pancreas.
Foamy Gland Carcinoma of the Prostate in Needle Biopsy: Incidence, Gleason Grade, and Comparative ?-Methylacyl-CoA Racemase vs. ERG Expression.
Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Carcinoma, Basal Cell
Expression of alpha-methylacyl-CoA racemase (P504S) in sebaceous neoplasms.
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Carcinoma, Ductal
Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis.
Carcinoma, Endometrioid
Comparative analysis of Napsin A, alpha-methylacyl-coenzyme A racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumours.
Utility of ?-methylacyl-coenzyme-A racemase (p504s) immunohistochemistry in distinguishing endometrial clear cell carcinomas from serous and endometrioid carcinomas.
Carcinoma, Hepatocellular
Abundant expression of AMACR in many distinct tumour types.
Alpha-methylacyl-CoA racemase (AMACR/P504S) can distinguish hepatocellular carcinoma and dysplastic hepatocytes from benign nondysplastic hepatocytes.
AMACR is not applicable as a diagnostic tool in hepatocellular carcinoma.
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Overexpression of ?-methylacyl-CoA racemase is associated with CTNNB1 mutations in hepatocellular carcinomas.
Significance of overexpression of alpha methylacyl-coenzyme A racemase in hepatocellular carcinoma.
Carcinoma, Intraductal, Noninfiltrating
Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis.
CDK19 as a diagnostic marker for high-grade prostatic intraepithelial neoplasia.
[Diagnostic value of estimation of ERG expression in prostate adenocarcinoma and high-grade prostatic intraepithelial neoplasia].
Carcinoma, Medullary
Cadherin-17 and SATB2 Are Sensitive and Specific Immunomarkers for Medullary Carcinoma of the Large Intestine.
Carcinoma, Neuroendocrine
Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
Alpha-methylacyl-coenzyme A racemase expression in neuroendocrine neoplasms of the stomach.
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Gastric neuroendocrine carcinoma with positive staining for prostate cancer markers including prostate-specific antigen and alpha-methylacyl-CoA racemase.
Carcinoma, Ovarian Epithelial
Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer.
Carcinoma, Papillary
AMACR Positive Papillary Renal Adenomatosis and Multifocal Papillary Carcinoma in End Stage Renal Disease.
Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma.
Carcinoma, Renal Cell
A renal cell carcinoma with components of both chromophobe and papillary carcinoma.
Abundant expression of AMACR in many distinct tumour types.
Adult Nephroblastoma with Predominant Epithelial Component: A Differential Diagnostic Candidate of Papillary Renal Cell Carcinoma and Metanephric Adenoma-Report of Three Cases.
Adult papillary renal tumor with oncocytic cells: clinicopathologic, immunohistochemical, and cytogenetic features of 10 cases.
Alpha-methyl CoA racemase expression in renal cell carcinomas.
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
AMACR Positive Papillary Renal Adenomatosis and Multifocal Papillary Carcinoma in End Stage Renal Disease.
Atypical Renal Cysts: A Morphologic, Immunohistochemical, and Molecular Study.
Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S.
Clear cell papillary renal cell carcinoma: a case report and literature review.
Clear Cell Renal Cell Carcinoma Metastatic to the Gynecologic Tract: A Clinicopathologic Analysis of 17 Cases.
Clear Cell Renal Cell Carcinoma With Borderline Features of Clear Cell Papillary Renal Cell Carcinoma: Combined Morphologic, Immunohistochemical, and Cytogenetic Analysis.
Collecting duct carcinoma of the kidney: an immunohistochemical evaluation of the use of antibodies for differential diagnosis.
Do Clear Cell Papillary Renal Cell Carcinomas Have Malignant Potential?
Do clear cell papillary renal cell carcinomas have malignant potential? Diolombi ML, Cheng L, Argani P, Epstein JI.Am J Surg Pathol. December 2015;39(12):1621-1634.
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Expression of alpha-methylacyl-CoA racemase correlates with histopathologic grading in noninvasive bladder cancer.
Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma.
Gene expression profiling of clear cell papillary renal cell carcinoma: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.
Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: significant immunophenotypic overlap warrants diagnostic caution.
Immunohistochemical detection of P504S in primary and metastatic renal cell carcinomas.
Immunohistochemical phenotype and molecular pathological characteristics of metanephric adenoma.
Papillary renal cell carcinoma with diffuse clear cells and thyroid-like macrofollicular areas.
Peroxisomal disorders affecting phytanic acid alpha-oxidation: a review.
Profiling and classification tree applied to renal epithelial tumours.
Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma.
Renal cell carcinoma with mixed features of papillary and clear cell cytomorphology: a fluorescent in situ hybridization study.
Renal cell carcinomas with papillary architecture and clear cell components: the utility of immunohistochemical and cytogenetical analyses in differential diagnosis.
Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study.
The utility of alpha-methyl CoA racemase (P504S) expression as a marker of renal cell carcinomas.
Tubulocystic renal cell carcinoma with poorly differentiated foci is indicative of aggressive behavior: clinicopathologic study of two cases and review of the literature.
Tubulocystic renal cell carcinoma: Report of a rare case.
Useful immunohistochemical panel for differentiating clear cell papillary renal cell carcinoma from its mimics.
[Diagnostic utility of immunohistochemistry in differential diagnosis of renal tumors with oncocytic features].
[Expression of cadherin17 in metanephric adenoma and its value in differential diagnosis].
[Metastatic renal cell carcinoma: a clinicopathological analysis of 196 cases].
Carcinoma, Squamous Cell
Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
Clinical significance of the expression of alpha-methylacyl-CoA racemase in squamous cell carcinoma and adenocarcinoma of the lung.
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Cerebellar Ataxia
AMACR mutations cause late-onset autosomal recessive cerebellar ataxia.
Charcot-Marie-Tooth Disease
Role of Alpha-methylacyl-CoA racemase gene in pathogenecity of CMT patients.
Cholelithiasis
Asymptomatic retinal dysfunction in alpha-methylacyl-CoA racemase deficiency.
Chondroma
Biomarkers of chondrosarcoma.
Chondrosarcoma
?-methylacyl-CoA racemase (AMACR) expression in chordomas differentiates them from chondrosarcomas.
Biomarkers of chondrosarcoma.
Chordoma
?-methylacyl-CoA racemase (AMACR) expression in chordomas differentiates them from chondrosarcomas.
Colitis, Ulcerative
AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
Colitis-Associated Neoplasms
Combined alpha-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease.
Colonic Neoplasms
A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma.
Alpha-Methylacyl-CoA Racemase Expression is Upregulated in Gastric Adenocarcinoma: A Study of 249 Cases.
AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance.
Same difference: A pilot study of cyclin D1, bcl-2, AMACR, and ALDH-1 identifies significant differences in expression between primary colon adenocarcinoma and its metastases.
Sigmoid Colon Adenocarcinoma with Isolated Loss of PMS2 Presenting in a Patient with Synchronous Prostate Cancer with Intact MMR: Diagnosis and Analysis of the Family Pedigree.
Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer.
[The value of alpha-methylacyl-CoA racemase expression in the progression of colonic carcinoma].
Colorectal Neoplasms
A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma.
Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer.
Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer.
Alpha-methylacyl-CoA racemase/P504S overexpression in colorectal carcinoma is correlated with tumor differentiation.
alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation.
AMACR expression in colorectal cancer is associated with left-sided tumor localization.
Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance.
Expression of alpha-methylacyl-CoA racemase (P504S) in sebaceous neoplasms.
Expression of alpha-methylacyl-CoA racemase correlates with histopathologic grading in noninvasive bladder cancer.
Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
Crohn Disease
AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
Cystadenocarcinoma, Mucinous
Alpha-methylacyl-coenzyme a racemase-expressing urachal adenocarcinoma of the abdominal wall.
Cystadenoma, Papillary
Papillary cystadenoma of the epididymis and broad ligament: morphologic and immunohistochemical overlap with clear cell papillary renal cell carcinoma.
Dysplastic Nevus Syndrome
?-Methylacyl-coenzyme A racemase (AMACR, p504s) is a marker to distinguish malignant melanomas from dysplastic nevi and melanocytic nevi.
Endodermal Sinus Tumor
Comparative analysis of Napsin A, alpha-methylacyl-coenzyme A racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumours.
Endometrial Neoplasms
Utility of ?-methylacyl-coenzyme-A racemase (p504s) immunohistochemistry in distinguishing endometrial clear cell carcinomas from serous and endometrioid carcinomas.
Extranodal Extension
Circulating mRNA Signature as a Marker for High-Risk Prostate Cancer.
Gastrointestinal Stromal Tumors
AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis.
Glioblastoma
Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma.
Glioma
Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma.
Inflammatory Bowel Diseases
AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
Combined alpha-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease.
Kidney Diseases
AMACR Positive Papillary Renal Adenomatosis and Multifocal Papillary Carcinoma in End Stage Renal Disease.
Kidney Failure, Chronic
AMACR Positive Papillary Renal Adenomatosis and Multifocal Papillary Carcinoma in End Stage Renal Disease.
Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile.
Kidney Neoplasms
Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer.
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Fluorescence in situ hybridization as an adjunct tool in the diagnosis of primary and metastatic renal cell carcinoma in fine needle aspiration specimens.
Immunohistochemical detection of P504S in primary and metastatic renal cell carcinomas.
The utility of alpha-methyl CoA racemase (P504S) expression as a marker of renal cell carcinomas.
Liposarcoma, Myxoid
Scattered genomic amplification in dedifferentiated liposarcoma.
Liver Diseases
Plasma analysis of di- and trihydroxycholestanoic acid diastereoisomers in peroxisomal alpha-methylacyl-CoA racemase deficiency.
Liver Neoplasms
Oncogenic Activity of Solute Carrier Family 45 Member 2 and Alpha-Methylacyl-Coenzyme A Racemase Gene Fusion Is Mediated by Mitogen-Activated Protein Kinase.
Lung Neoplasms
Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
Lymphoma
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
Melanoma
?-Methylacyl-coenzyme A racemase (AMACR, p504s) is a marker to distinguish malignant melanomas from dysplastic nevi and melanocytic nevi.
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer.
Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma with a micropapillary pattern: cases report and literature review.
Mesothelioma
The expression and clinical effects of alpha-methylacyl-CoA racemase (AMACR/ P504S) as an immunohistochemical marker in malign pleural mesothelioma.
Mesothelioma, Malignant
The expression and clinical effects of alpha-methylacyl-CoA racemase (AMACR/ P504S) as an immunohistochemical marker in malign pleural mesothelioma.
Motor Neuron Disease
Characterization of the mutant ?-subunit of ?-hexosaminidase for dimer formation responsible for the adult form of Sandhoff disease with the motor neuron disease phenotype.
Nasopharyngeal Carcinoma
AMACR overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma.
Neoplasm Metastasis
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation.
AMACR overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma.
An analysis of the p63/alpha-methylacyl coenzyme A racemase immunohistochemical cocktail stain in prostate needle biopsy specimens and tissue microarrays.
Burned-out Prostate Cancer ? Primary Metastatic Cancer Not Detected on Repeat Biopsy.
Endobronchial metastasis from prostate cancer mimicking primary lung cancer.
Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma.
Same difference: A pilot study of cyclin D1, bcl-2, AMACR, and ALDH-1 identifies significant differences in expression between primary colon adenocarcinoma and its metastases.
Neoplasms
"Mucin"-secreting papillary renal cell carcinoma: clinicopathological, immunohistochemical, and molecular genetic analysis of seven cases.
?-Methylacyl-CoA racemase (AMACR) serves as a prognostic biomarker for the early recurrence/metastasis of HCC.
?-Methylacyl-CoA racemase (AMACR): Metabolic enzyme, drug metabolizer and cancer marker P504S.
?-Methylacyl-CoA racemase (P504S) is a useful marker for the differential diagnosis of solid pseudopapillary neoplasm of the pancreas.
?-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study.
A Case of a Malignant Cutaneous Mixed Tumor (Chondroid Syringoma) of the Scapula Treated With Staged Margin-Controlled Excision.
A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma.
A nonclassic CCAAT enhancer element binding protein binding site contributes to alpha-methylacyl-CoA racemase expression in prostate cancer.
A Novel Monoclonal Antibody Against Alpha-Methylacyl-CoA Racemase Applicable for Paraffin-Embedded Tissues and Diagnostics of Prostate Cancer.
A Rare Case of Renal Cell Carcinoma With Leiomyomatous Stroma and Concomitant Ruptured Adrenal Aneurysm.
A Rare Partner of TFE3 in the Xp11 Translocation Renal Cell Carcinoma: Clinicopathological Analyses and Detection of MED15-TFE3 Fusion.
A renal cell carcinoma with components of both chromophobe and papillary carcinoma.
A statistical method for identifying differential gene-gene co-expression patterns.
A study on the AMACR catalysed elimination reaction and its application to inhibitor testing.
Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer.
Abundant expression of AMACR in many distinct tumour types.
Adult Nephroblastoma with Predominant Epithelial Component: A Differential Diagnostic Candidate of Papillary Renal Cell Carcinoma and Metanephric Adenoma-Report of Three Cases.
Adult papillary renal tumor with oncocytic cells: clinicopathologic, immunohistochemical, and cytogenetic features of 10 cases.
Age-associated changes in alpha-methyl CoA racemase (AMACR) expression in nonneoplastic prostatic tissues.
ALK-rearranged renal cell carcinoma with a novel PLEKHA7-ALK translocation and metanephric adenoma-like morphology.
Alpha-methyl CoA racemase expression in renal cell carcinomas.
Alpha-methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies.
Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.
alpha-methylacyl coenzyme A racemase is immunoreactive in extramammary Paget disease.
Alpha-methylacyl coenzyme A racemase overexpression in gallbladder carcinoma confers an independent prognostic indicator.
alpha-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer.
Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer.
Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer.
Alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry in Barrett's and colorectal mucosa: only significant overexpression favours a diagnosis of intraepithelial neoplasia.
Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma.
Alpha-methylacyl-CoA racemase (AMACR/P504S) can distinguish hepatocellular carcinoma and dysplastic hepatocytes from benign nondysplastic hepatocytes.
Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression.
Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone.
Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma.
Alpha-Methylacyl-CoA Racemase Expression is Upregulated in Gastric Adenocarcinoma: A Study of 249 Cases.
Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis.
Alpha-methylacyl-CoA racemase--an 'obscure' metabolic enzyme takes centre stage.
Alpha-methylacyl-CoA racemase/P504S overexpression in colorectal carcinoma is correlated with tumor differentiation.
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy.
alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation.
Alpha-methylacyl-coenzyme A racemase expression in neuroendocrine neoplasms of the stomach.
Alternative spliced variants of the alpha-methylacyl-CoA racemase gene and their expression in prostate cancer.
AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis.
AMACR expression in colorectal cancer is associated with left-sided tumor localization.
AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
AMACR is highly expressed in gastric adenomas and intestinal-type carcinomas.
AMACR is not applicable as a diagnostic tool in hepatocellular carcinoma.
AMACR overexpression acts as a negative prognostic factor in oral squamous cell carcinoma.
AMACR overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma.
AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk.
AMACR: an emerging diagnostic and prognostic tool in systemic malignancies.
An analysis of the p63/alpha-methylacyl coenzyme A racemase immunohistochemical cocktail stain in prostate needle biopsy specimens and tissue microarrays.
Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia.
Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review.
Association of polymorphisms of PTEN, AKT1, PI3K, AR, and AMACR genes in patients with prostate cancer.
Atypical small acinar proliferation: biopsy artefact or distinct pathological entity?
BAP1-Mutated Clear Cell Renal Cell Carcinoma.
Biphasic squamoid alveolar renal carcinoma with positive CD57 expression: A clinicopathologic study of three cases.
Branched fatty acids in dairy and beef products markedly enhance alpha-methylacyl-CoA racemase expression in prostate cancer cells in vitro.
CA125-producing clear cell adenocarcinoma arising from the upper ureter and renal pelvis.
Cell type specific gene expression analysis of prostate needle biopsies resolves tumor tissue heterogeneity.
Circulating mRNA Signature as a Marker for High-Risk Prostate Cancer.
Circulating Prostate Cells Found in Men with Benign Prostate Disease Are P504S Negative: Clinical Implications.
Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S.
Clear cell papillary renal cell carcinoma and clear cell renal cell carcinoma arising in acquired cystic disease of the kidney: an immunohistochemical and genetic study.
Clear cell papillary renal cell carcinoma-like tumors in patients with von Hippel-Lindau disease are unrelated to sporadic clear cell papillary renal cell carcinoma.
Clear cell papillary renal cell carcinoma: a clinicopathologic analysis of 6 cases.
Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity.
Clear cell papillary renal cell carcinoma: a review.
Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile.
Clear cell-papillary renal cell carcinoma of the kidney not associated with end-stage renal disease: clinicopathologic correlation with expanded immunophenotypic and molecular characterization of a large cohort with emphasis on relationship with renal angiomyoadenomatous tumor.
Clinical significance of the expression of alpha-methylacyl-CoA racemase in squamous cell carcinoma and adenocarcinoma of the lung.
Clinical, pathologic, and molecular features of early-onset colorectal carcinoma.
Clinicopathological Findings on 28 Cases with XP11.2 Renal Cell Carcinoma.
Coexistent loss of INI1 and BRG1 expression in a rhabdoid renal cell carcinoma (RCC): implications for a possible role of SWI/SNF complex in the pathogenesis of RCC.
Combined ?-methylacyl-CoA racemase inhibition and docetaxel treatment reduce cell proliferation and decrease expression of heat shock protein 27 in androgen receptor-variant-7-positive prostate cancer cells.
Combined alpha-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease.
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.
Comparative analysis of Napsin A, alpha-methylacyl-coenzyme A racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumours.
Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer.
Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes.
Conversion of prostate cancer from hormone independency to dependency due to AMACR inhibition: involvement of increased AR expression and decreased IGF1 expression.
Correlation of cyclin D1, HER2, and AMACR expressions with histologic grade in bladder urothelial carcinomas.
Current Knowledge on the Function of ?-Methyl Acyl-CoA Racemase in Human Diseases.
Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon.
Design, synthesis, and in vitro testing of alpha-methylacyl-CoA racemase inhibitors.
Detection of Alpha-Methylacyl-CoA Racemase (AMACR), a Biomarker of Prostate Cancer, in Patient Blood Samples Using a Nanoparticle Electrochemical Biosensor.
Detection of alpha-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients.
Detection of prostate cancer by alpha-methylacyl CoA racemase (P504S) in needle biopsy specimens previously reported as negative for malignancy.
Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy.
Diagnostic roles of proliferative markers in pathological Grade of T1 Urothelial Bladder Cancer.
Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations.
Diagnostic utility of alpha-methylacyl CoA racemase (P504S) on prostate needle biopsy.
Diagnostic utility of P504S/p63 cocktail, prostate-specific antigen, and prostatic acid phosphatase in verifying prostatic carcinoma involvement in seminal vesicles: a study of 57 cases of radical prostatectomy specimens of pathologic stage pT3b.
Diagnostic utility of triple antibody (AMACR, HMWCK and P63) stain in prostate neoplasm.
Differential expression of alpha-methylacyl coenzyme A racemase in adenocarcinomas of the small and large intestines.
Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance.
Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S).
Distal Tubular Hyperplasia: A Proposal for a Unique Form of Renal Tubular Proliferation Distinct From Papillary Adenoma.
Ductal adenocarcinoma of the prostate: current opinion and controversies.
Embryonal Origin of Metanephric Adenoma and its Differential Diagnosis.
Evaluation of role of alpha-methyl acyl-coenzyme A racemase/P504S and high molecular weight cytokeratin in diagnosing prostatic lesions.
Evaluation ofalpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers.
EWSR1-PATZ1 fusion renal cell carcinoma: a recurrent gene fusion characterizing thyroid-like follicular renal cell carcinoma.
Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates prostate cancer growth.
Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer.
Expression of Alpha - Methylacyl - Coenzyme A Racemase (AMACR) in Colorectal Neoplasia.
Expression of alpha-methylacyl-CoA racemase (P504S) in sebaceous neoplasms.
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Expression of alpha-methylacyl-CoA racemase correlates with histopathologic grading in noninvasive bladder cancer.
Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma.
Expression of genes and proteins specific for prostate cancer.
Expression of p53 predicts risk of prevalent and incident advanced neoplasia in patients with Barrett's esophagus and epithelial changes indefinite for dysplasia.
Expression of the Y-Encoded TSPY is Associated with Progression of Prostate Cancer.
Expression profile of MAGI2 gene as a novel biomarker in combination with major deregulated genes in prostate cancer.
Expression profiling identifies a novel alpha-methylacyl-CoA racemase exon with fumarate hydratase homology.
EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma.
Fine needle aspiration biopsy of renal mucinous tubular and spindle cell carcinoma: Report of two cases.
Fluorescence in situ hybridization as an adjunct tool in the diagnosis of primary and metastatic renal cell carcinoma in fine needle aspiration specimens.
Foamy Gland Carcinoma of the Prostate in Needle Biopsy: Incidence, Gleason Grade, and Comparative ?-Methylacyl-CoA Racemase vs. ERG Expression.
Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation.
Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.
GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics.
Heterogeneous expression of alpha-methylacyl-CoA racemase in prostatic cancer correlates with Gleason score.
High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
High-Grade Urothelial Carcinoma of Bladder Transforming to Micropapillary Variant on Follow-Up.
High-Throughput Screen Identifies Novel Inhibitors of Cancer Biomarker {alpha}-Methylacyl Coenzyme A Racemase (AMACR/P504S).
Histogenesis of clear cell adenocarcinoma in the urinary tract: evidence of urothelial origin.
Horseradish peroxidase and aptamer dual-functionalized nanoprobe for the amplification detection of alpha-methylacyl-CoA racemase.
How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers?
Human telomerase and alpha-methylacyl-coenzyme A racemase in prostatic carcinoma. A comparative immunohistochemical study.
Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.
Identification and characterization of Birt-Hogg-Dubé associated renal carcinoma.
Identification of Clinically Significant Prostate Cancer by Combined PCA3 and AMACR mRNA Detection in Urine Samples.
Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer.
Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: significant immunophenotypic overlap warrants diagnostic caution.
Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Immunohistochemical detection of P504S in primary and metastatic renal cell carcinomas.
Immunohistochemical Reactivity of Prostate-Specific Markers for Salivary Duct Carcinoma.
Immunohistochemistry in diagnostic surgical pathology of the prostate.
Immunophenotype and cytogenetics of mucinous tubular and spindle cell carcinoma of the kidney.
In situ and intraductal epithelial proliferations of prostate: definitions and treatment implications. Part 1: Prostatic intraepithelial neoplasia.
Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.
Is atypical adenomatous hyperplasia of the prostate a precursor lesion?
Is there a role for prostate tumour overexpressed-1 in the diagnosis of HGPIN and of prostatic adenocarcinoma? A comparison with alpha-methylacyl CoA racemase.
Isolation of human prostatic epithelial plasma membranes for proteomics using mirror image tissue banking of radical prostatectomy specimens.
Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
Malignant transformation of human benign prostate epithelial cells by high linear energy transfer alpha-particles.
Metanephric adenoma: association between the imaging features of contrast-enhanced ultrasound and clinicopathological characteristics.
Metastasis from papillary renal cell carcinoma masquerading as primary ovarian clear cell tumor.
Molecular diagnosis of renal cell neoplasms: the usefulness of immunohistochemistry and fluorescence in situ hybridization.
Molecular-genetic analysis is essential for accurate classification of renal carcinoma resembling Xp11.2 translocation carcinoma.
MORPHOLOGICAL DIAGNOSIS OF PANCREATIC NEUROENDOCRINE TUMORS (REVIEW AND CASE REPORT).
Morphological, immunohistochemical, and chromosomal analysis of multicystic chromophobe renal cell carcinoma, an architecturally unusual challenging variant.
Mucinous tubular and spindle cell carcinoma of kidney is probably a variant of papillary renal cell carcinoma with spindle cell features.
Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid change.
New Molecular Markers for Prostate Tumor Imaging: A Study on 2-Methylene Substituted Fatty Acids as New AMACR Inhibitors.
Novel 2-arylthiopropanoyl-CoA inhibitors of ?-methylacyl-CoA racemase 1A (AMACR; P504S) as potential anti-prostate cancer agents.
Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.
Oncocytic papillary renal cell carcinoma with inverted nuclear pattern: distinct subtype with an indolent clinical course.
Oncocytic renal cell carcinoma having papillotubular growth: rare morphological variant of papillary renal cell carcinoma.
Oncogenic Activity of Solute Carrier Family 45 Member 2 and Alpha-Methylacyl-Coenzyme A Racemase Gene Fusion Is Mediated by Mitogen-Activated Protein Kinase.
Orthotopic tumorgrafts in nude mice: A new method to study human prostate cancer.
Ovarian Seromucinous Borderline Tumor and Clear Cell Carcinoma: An Unusual Combination.
Overlapping Immunohistochemical Features of Adenocarcinoma of the Nonpigmented Ciliary Body Epithelium and Renal Cell Carcinoma.
P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies.
P504S immunostaining boosts diagnostic resolution of "suspicious" foci in prostatic needle biopsy specimens.
P504S: a new molecular marker for the detection of prostate carcinoma.
Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases.
Papillary renal cell carcinoma with diffuse clear cells and thyroid-like macrofollicular areas.
Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features.
Papillary Renal Neoplasm With Reverse Polarity: A Morphologic, Immunohistochemical, and Molecular Study.
Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study.
Peroxisomal disorders affecting phytanic acid alpha-oxidation: a review.
Phytanic acid: measurement of plasma concentrations by gas-liquid chromatography-mass spectrometry analysis and associations with diet and other plasma fatty acids.
Preparation and characterization of the antibody recognizing AMACR inside its catalytic center.
Primary renal myxofibrosarcoma.
Primary retroperitoneal renal cell carcinoma associated with transcription EB gene fusion.
Primary small cell carcinoma of prostate without immunoreactive neuroendocrine proteins but with expressions of KIT and platelet-derived growth factor-?.
Prognostic Significance of alpha-Methylacyl-CoA Racemase Among Men With High Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsies.
Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma.
Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein.
Prostate cancer marker panel with single cell sensitivity in urine.
Prostate cancer stem cells: do they have a Basal or luminal phenotype?
Prostatic adenocarcinoma oncocytic variant: Case report and literature review.
Quantitative analysis of a panel of gene expression in prostate cancer--with emphasis on NPY expression analysis.
Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements.
Recurrent KRAS mutations identified in papillary renal neoplasm with reverse polarity-a comparative study with papillary renal cell carcinoma.
Relationship between alpha-methylacyl-coenzyme A racemase expression and mucin phenotype in gastric cancer.
Renal cell carcinoma in tuberous sclerosis complex.
Renal-type clear cell carcinoma of prostate: A case report and review of literature.
Response to the letter by Shailendra Kapoor: AMACR is an emerging diagnostic and prognostic tool in systemic malignancies.
Retroperitoneal sclerosing PEComa with melanin pigmentation and granulomatous inflammation-a rare association within an uncommon tumor.
Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis.
S-100A1 Is a Reliable Marker in Distinguishing Nephrogenic Adenoma From Prostatic Adenocarcinoma.
Same difference: A pilot study of cyclin D1, bcl-2, AMACR, and ALDH-1 identifies significant differences in expression between primary colon adenocarcinoma and its metastases.
Selective Androgen Receptor Modulator S42 Suppresses Prostate Cancer Cell Proliferation.
Semen AMACR protein as a novel method for detecting prostate cancer.
Sertoli cell tumor of the testis, not otherwise specified, presenting extensive hemorrhage and overexpression of alpha-methylacyl-CoA racemase (AMACR/P504S).
Sex-dependent expression of prostatic markers and hormone receptors in cystic tumor of the atrioventricular node: A histopathological study of three cases.
Significance of overexpression of alpha methylacyl-coenzyme A racemase in hepatocellular carcinoma.
Significance of prostate cancer missed on needle biopsy tools for retrieving missed cancer.
Skene's gland adenocarcinoma with intestinal differentiation: A case report and literature review.
Small cell neuroendocrine carcinoma of the prostate: Incidence and a report of four cases with an examination of KIT and PDGFRA.
Strength of molecular cytogenetic analyses for adjusting the diagnosis of renal cell carcinomas with both clear cells and papillary features: a study of three cases.
t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma.
The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and ?-methylacyl-CoA-racemase markers.
The expression and clinical effects of alpha-methylacyl-CoA racemase (AMACR/ P504S) as an immunohistochemical marker in malign pleural mesothelioma.
The expressions of AMACR and iNOS in prostate adenocarcinomas.
The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.
The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase.
The significance of the P504S expression pattern of high-grade prostatic intraepithelial neoplasia (HGPIN) with and without adenocarcinoma of the prostate in biopsy and radical prostatectomy specimens.
The utility of alpha-methyl CoA racemase (P504S) expression as a marker of renal cell carcinomas.
Thyroid-like Follicular Carcinoma of the Kidney and Papillary Renal Cell Carcinoma with Thyroid-like Feature: Comparison of Two Cases and Literature Review.
TMPRSS2-ERG fusion impacts anterior tumor location in men with prostate cancer.
Tubulocystic renal cell carcinoma in the left kidney: a case report.
Tubulocystic renal cell carcinoma is an entity that is immunohistochemically and genetically distinct from papillary renal cell carcinoma.
Tubulocystic renal cell carcinoma with poorly differentiated foci is indicative of aggressive behavior: clinicopathologic study of two cases and review of the literature.
Tubulocystic renal cell carcinoma: Report of a rare case.
Uncommon Localization of Extrarenal Xp11.2 Translocation-associated Renal Cell Carcinoma (RCC): Case Report.
Updates in the Pathologic Diagnosis and Classification of Epithelial Neoplasms of Urachal Origin.
Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
Use of p63/P504S monoclonal antibody cocktail in immunohistochemical staining of prostate tissue.
Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens.
Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer.
Utility of ERG Versus AMACR Expression in Diagnosis of Minimal Adenocarcinoma of the Prostate in Needle Biopsy Tissue.
Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy.
Utility of immunohistochemistry markers in the interpretation of post-high-intensive focussed ultrasound prostate biopsy cores.
Utility of racemase and other immunomarkers in the detection of adenocarcinoma in prostatic tissue damaged by high intensity focused ultrasound therapy.
Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.
Variants in the alpha-Methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma.
Virtual microscopy in prostate histopathology: simultaneous viewing of biopsies stained sequentially with hematoxylin and eosin, and alpha-methylacyl-coenzyme A racemase/p63 immunohistochemistry.
Xp11 translocation renal cell carcinoma in adults: a clinicopathological and comparative genomic hybridization study.
Xp11.2 translocation renal cell carcinoma with multiple bone metastases: A case report.
Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma with a micropapillary pattern: cases report and literature review.
[Achievements in morphological diagnosis of prostatic cancer: alpha-methylacyl-coenzyme-A-racemase--a new marker of malignant cell transformation]
[Acquired cystic kidney disease-associated renal cell carcinoma: a clinicopathologic study of three cases].
[Basal-luminal epithelial cell differentiation in prostate cancer is associated with epithelial-mesenchymal transition and epithelium migration in the mesenchyme].
[Clinical and morphological characteristics of thyroid tumors in children of the Chelyabinsk Region].
[Clinicopathological analysis of clear cell renal cell carcinoma with hemangioblastoma component].
[CXCR4 combined with P504S or P63 in differential diagnosis of benign and malignant prostatic diseases]
[Detection of AMACR (P504S), P63 and 34betaE12 cocktail in the early diagnosis of prostate cancer]
[Diagnostic utility of immunohistochemistry in differential diagnosis of renal tumors with oncocytic features].
[Differential diagnosis of prostate cancer: impact of pattern analysis and immunohistochemistry]
[Evaluation of p63 and p504s markers for the diagnosis of prostate cancer]
[Expression of cadherin17 in metanephric adenoma and its value in differential diagnosis].
[Fatty acid synthase in the diagnosis of prostate neoplasms].
[Gleason histologic grading of prostate carcinoma in relation to serum PSA, PSA in situ and immunohistochemical expression of 34 beta E12 and P504S]
[Multi-modality MRI parameters correlate with the expression of the P504s protein in prostate cancer].
[Related biomarkers in the diagnosis of prostate cancer].
[Significance of P504s in distinction between solid pseudopapillary tumor of pancreas and pancreatic neuroendocrine tumors].
[Small suggestive lesions of the prostate Histological and immunohistochemical analyses -- report of the uropathology consultation service]
[Tubulocystic carcinoma of the kidney].
Neoplasms, Germ Cell and Embryonal
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Neoplasms, Glandular and Epithelial
S-100A1 Is a Reliable Marker in Distinguishing Nephrogenic Adenoma From Prostatic Adenocarcinoma.
Neoplastic Cells, Circulating
Detection of alpha-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients.
Nephrolithiasis
AMACR Positive Papillary Renal Adenomatosis and Multifocal Papillary Carcinoma in End Stage Renal Disease.
Neuroblastoma
Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors.
Neuroendocrine Tumors
?-Methylacyl-CoA racemase (P504S) is a useful marker for the differential diagnosis of solid pseudopapillary neoplasm of the pancreas.
Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
Alpha-methylacyl-coenzyme A racemase expression in neuroendocrine neoplasms of the stomach.
[Significance of P504s in distinction between solid pseudopapillary tumor of pancreas and pancreatic neuroendocrine tumors].
Nevus
?-Methylacyl-coenzyme A racemase (AMACR, p504s) is a marker to distinguish malignant melanomas from dysplastic nevi and melanocytic nevi.
Nevus, Pigmented
?-Methylacyl-coenzyme A racemase (AMACR, p504s) is a marker to distinguish malignant melanomas from dysplastic nevi and melanocytic nevi.
Ovarian Neoplasms
Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer.
Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma.
Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer.
Paget Disease, Extramammary
alpha-methylacyl coenzyme A racemase is immunoreactive in extramammary Paget disease.
Pancreatic Neoplasms
Alpha-methylacyl-CoA racemase is expressed in a majority of pancreatic neoplasms of neuroendocrine, acinar, and solid pseudopapillary differentiation.
Papilloma
[Antigen retrieval immunohistochemistry under the influence of pH value and time]
Papillomavirus Infections
Clinical, pathologic, and molecular features of early-onset colorectal carcinoma.
Parasitic Diseases
?-Methylacyl-CoA racemase (AMACR): Metabolic enzyme, drug metabolizer and cancer marker P504S.
Peripheral Nervous System Diseases
Role of Alpha-methylacyl-CoA racemase gene in pathogenecity of CMT patients.
Peroxisomal Disorders
Asymptomatic retinal dysfunction in alpha-methylacyl-CoA racemase deficiency.
Prostatic Diseases
[CXCR4 combined with P504S or P63 in differential diagnosis of benign and malignant prostatic diseases]
Prostatic Hyperplasia
Age-associated changes in alpha-methyl CoA racemase (AMACR) expression in nonneoplastic prostatic tissues.
Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone.
Can p503s, p504s and p510s gene expression in peripheral-blood be useful as a marker of prostatic cancer?
Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate.
Heterogeneous expression of alpha-methylacyl-CoA racemase in prostatic cancer correlates with Gleason score.
[Detection of AMACR (P504S), P63 and 34betaE12 cocktail in the early diagnosis of prostate cancer]
[Detection of P504S (alpha-methylacyl-CoA racemase) in prostatic adenocarcinomas]
Prostatic Intraepithelial Neoplasia
Age-associated changes in alpha-methyl CoA racemase (AMACR) expression in nonneoplastic prostatic tissues.
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.
alpha-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer.
Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer.
Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone.
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia.
Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review.
Branched fatty acids in dairy and beef products markedly enhance alpha-methylacyl-CoA racemase expression in prostate cancer cells in vitro.
Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer.
Detection of Alpha-Methylacyl-CoA Racemase (AMACR), a Biomarker of Prostate Cancer, in Patient Blood Samples Using a Nanoparticle Electrochemical Biosensor.
Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy.
Diagnostic utility of P504S/p63 cocktail, prostate-specific antigen, and prostatic acid phosphatase in verifying prostatic carcinoma involvement in seminal vesicles: a study of 57 cases of radical prostatectomy specimens of pathologic stage pT3b.
Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer.
Immunohistochemistry in diagnostic surgical pathology of the prostate.
Is there a role for prostate tumour overexpressed-1 in the diagnosis of HGPIN and of prostatic adenocarcinoma? A comparison with alpha-methylacyl CoA racemase.
P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies.
P504S immunostaining boosts diagnostic resolution of "suspicious" foci in prostatic needle biopsy specimens.
Prognostic Significance of alpha-Methylacyl-CoA Racemase Among Men With High Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsies.
The significance of the P504S expression pattern of high-grade prostatic intraepithelial neoplasia (HGPIN) with and without adenocarcinoma of the prostate in biopsy and radical prostatectomy specimens.
Use of p63/P504S monoclonal antibody cocktail in immunohistochemical staining of prostate tissue.
Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens.
Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer.
[Achievements in morphological diagnosis of prostatic cancer: alpha-methylacyl-coenzyme-A-racemase--a new marker of malignant cell transformation]
[Detection of AMACR (P504S), P63 and 34betaE12 cocktail in the early diagnosis of prostate cancer]
[Fatty acid synthase in the diagnosis of prostate neoplasms].
Prostatic Neoplasms
?-Methylacyl-CoA racemase (AMACR): Metabolic enzyme, drug metabolizer and cancer marker P504S.
?-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study.
A Continuous Assay for alpha-Methylacyl-CoA Racemase (AMACR) Using Circular Dichroism.
A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma.
A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer.
A nonclassic CCAAT enhancer element binding protein binding site contributes to alpha-methylacyl-CoA racemase expression in prostate cancer.
A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions.
A Novel Monoclonal Antibody Against Alpha-Methylacyl-CoA Racemase Applicable for Paraffin-Embedded Tissues and Diagnostics of Prostate Cancer.
A variant of the alpha-methyl-acyl-CoA racemase gene created by a deletion in exon 5 and its expression in prostate cancer.
A-methylacyl-CoA racemase (AMACR) and prostate-cancer risk: a meta-analysis of 4,385 participants.
Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases.
Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer.
Abundant expression of AMACR in many distinct tumour types.
Age-associated changes in alpha-methyl CoA racemase (AMACR) expression in nonneoplastic prostatic tissues.
Alpha-methyl CoA racemase expression in renal cell carcinomas.
Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
Alpha-methylacyl coenzyme A racemase as a marker for prostate cancer.
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.
alpha-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer.
Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer.
alpha-Methylacyl-CoA racemase (AMACR) in fine-needle aspiration specimens of prostate lesions.
Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma.
Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression.
Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone.
Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Alpha-methylacyl-CoA racemase and hepsin as urinary prostate cancer markers.
Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer.
Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis.
Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker.
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.
Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy.
alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation.
Alternative spliced variants of the alpha-methylacyl-CoA racemase gene and their expression in prostate cancer.
AMACR overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma.
AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk.
Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia.
Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods.
Ancillary alpha-methylacyl-CoA racemase immunocytochemistry in the diagnosis of adenocarcinoma of the prostate in urinary cytology: a case report.
Application of alpha-methylacyl coenzyme A racemase immunohistochemistry in the diagnosis of prostate cancer: a review.
Association of polymorphisms of PTEN, AKT1, PI3K, AR, and AMACR genes in patients with prostate cancer.
Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.
Bioconjugated, Single-Use Biosensor for the Detection of Biomarkers of Prostate Cancer.
Branched fatty acids in dairy and beef products markedly enhance alpha-methylacyl-CoA racemase expression in prostate cancer cells in vitro.
Can p503s, p504s and p510s gene expression in peripheral-blood be useful as a marker of prostatic cancer?
Cancer of unknown primary finally revealed to be a metastatic prostate cancer: a case report.
Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study.
Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer.
Comparison of the diagnostic value of fatty acid synthase (FASN) with alpha-methylacyl-CoA racemase (AMACR) as prostatic cancer tissue marker.
Conversion of prostate cancer from hormone independency to dependency due to AMACR inhibition: involvement of increased AR expression and decreased IGF1 expression.
Correction: Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer.
Correlations of dietary patterns with prostate health.
Current Knowledge on the Function of ?-Methyl Acyl-CoA Racemase in Human Diseases.
Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death.
Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon.
Detection of Alpha-Methylacyl-CoA Racemase (AMACR), a Biomarker of Prostate Cancer, in Patient Blood Samples Using a Nanoparticle Electrochemical Biosensor.
Detection of alpha-methylacyl-coenzyme A racemase in postradiation prostatic adenocarcinoma.
Detection of alpha-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients.
Detection of prostate cancer by alpha-methylacyl CoA racemase (P504S) in needle biopsy specimens previously reported as negative for malignancy.
Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations.
Diagnostic utility of ?-methylacyl CoA racemase (P504S) & HMWCK in morphologically difficult prostate cancer.
Diagnostic utility of a p63/alpha-methyl coenzyme A racemase (p504s) cocktail in ambiguous lesions of the prostate upon needle biopsy.
Diagnostic utility of a p63/alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate.
Diagnostic utility of alpha-methylacyl CoA racemase (P504S) on prostate needle biopsy.
Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature.
Dietary influences on tissue concentrations of phytanic acid and AMACR expression in the benign human prostate.
Differences between latent and clinical prostate carcinomas: lower cell proliferation activity in latent cases.
Differential expression of alpha-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance.
Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S).
Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.
Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs.
Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis.
Emerging biomarkers for the diagnosis and prognosis of prostate cancer.
Endobronchial metastasis from prostate cancer mimicking primary lung cancer.
Evaluation of Combined Quantification of PCA3 and AMACR Gene Expression for Molecular Diagnosis of Prostate Cancer in Moroccan Patients by RT-qPCR
Evaluation of routine application of P504S, 34betaE12 and p63 immunostaining on 250 prostate needle biopsy specimens.
Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates prostate cancer growth.
Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer.
Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer.
Expression of Alpha Methylacyl CoA Racemase (AMACR) in Gastric Adenocarcinoma and Its Correlation with Helicobacter pylori Infection.
Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate.
Expression of alpha-methylacyl-CoA racemase (P504S) in sebaceous neoplasms.
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma.
Expression of alpha-methylacyl-CoA racemase in vaginal gastric-type adenocarcinoma and uterine clear cell carcinoma.
Expression of alpha-methylacyl-coenzyme A racemase in dysplastic Barrett's epithelium.
Expression of alpha-methylacyl-coenzyme A racemase in nephrogenic adenoma.
Expression of the Y-Encoded TSPY is Associated with Progression of Prostate Cancer.
Expression profiling identifies a novel alpha-methylacyl-CoA racemase exon with fumarate hydratase homology.
Extended use of P504S positive primary circulating prostate cell detection to determine the need for initial prostate biopsy in a prostate cancer screening program in Chile.
Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysis.
Gastric neuroendocrine carcinoma with positive staining for prostate cancer markers including prostate-specific antigen and alpha-methylacyl-CoA racemase.
Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.
GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics.
Heterogeneous expression of alpha-methylacyl-CoA racemase in prostatic cancer correlates with Gleason score.
High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
High-Throughput Screen Identifies Novel Inhibitors of Cancer Biomarker {alpha}-Methylacyl Coenzyme A Racemase (AMACR/P504S).
Human prostate cancer precursors and pathobiology.
Human telomerase and alpha-methylacyl-coenzyme A racemase in prostatic carcinoma. A comparative immunohistochemical study.
Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.
Identification of a cell of origin for human prostate cancer.
Identification of Clinically Significant Prostate Cancer by Combined PCA3 and AMACR mRNA Detection in Urine Samples.
Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer.
Immunohistochemical biomarker validation in highly selective needle biopsy microarrays derived from mpMRI-characterized prostates.
Immunohistochemical Staining Characteristics of Nephrogenic Adenoma Using the PIN-4 Cocktail (p63, AMACR, and CK903) and GATA-3.
In situ sequencing identifies TMPRSS2-ERG fusion transcripts, somatic point mutations and gene expression levels in prostate cancers.
Induction of alpha-methylacyl-CoA racemase by miR-138 via up-regulation of ?-catenin in prostate cancer cells.
Is atypical adenomatous hyperplasia of the prostate a precursor lesion?
Is There a Role for Genetic Information in Risk Assessment and Decision Making in Prostate Cancer?
Is there a role for prostate tumour overexpressed-1 in the diagnosis of HGPIN and of prostatic adenocarcinoma? A comparison with alpha-methylacyl CoA racemase.
Is triple immunostaining with 34betaE12, p63, and racemase in prostate cancer advantageous? A tissue microarray study.
Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Lack of ERG-antibody in Benign Mimickers of Prostate Cancer.
Malignant Pleural Effusion from Metastatic Prostate Cancer: A Case Report with Unusual Cytologic Findings.
Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer.
Mn-doped ZnSe d-dots-based ?-methylacyl-CoA racemase probe for human prostate cancer cell imaging.
Modeling African American prostate adenocarcinoma by inducing defined genetic alterations in organoids.
Molecular cloning and preliminary analysis of the human alpha-methylacyl-CoA racemase promoter.
Molecular mechanisms, immune cell infiltration, and potential drugs for prostate cancer.
Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer.
Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer.
Netrin 1 and Alpha-Methyl Acylcoenzim-A Racemase in diagnosis of prostate cancer.
New circulating biomarkers for prostate cancer.
Novel 2-arylthiopropanoyl-CoA inhibitors of ?-methylacyl-CoA racemase 1A (AMACR; P504S) as potential anti-prostate cancer agents.
Oct4A is expressed by a subpopulation of prostate neuroendocrine cells.
Other biomarkers for detecting prostate cancer.
p16 Expression in Prostate Cancer and Nonmalignant Lesions: Novel Findings and Review of the Literature.
P504S expressing circulating prostate cells as a marker for prostate cancer.
P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies.
P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy.
Paneth cell-like change in benign prostate can account for P504S (AMACR) reactivity.
Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer.
Phase-Regulated Sensing Mechanism of MoS2 Based Nanohybrids toward Point-of-Care Prostate Cancer Diagnosis.
Phytanic acid, AMACR and prostate cancer risk.
Plasma phytanic acid concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition.
Polymorphic variants in alpha-methylacyl-CoA racemase and prostate cancer.
Prognostic Significance of alpha-Methylacyl-CoA Racemase Among Men With High Grade Prostatic Intraepithelial Neoplasia in Prostate Biopsies.
Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens.
Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein.
Prostate carcinogenesis induced by N-methyl-N-nitrosourea (mnu) in gerbils: Histopathological diagnosis and potential invasiveness mediated by extracellular matrix components.
Prostate Stroma Increases the Viability and Maintains the Branching Phenotype of Human Prostate Organoids.
PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer.
Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements.
Revisiting the Immunophenotype of Nephrogenic Adenoma.
RNA-based markers in biopsy cores with atypical small acinar proliferation: Predictive effect of T2E fusion positivity and MMP-2 upregulation for a subsequent prostate cancer diagnosis.
S-100A1 Is a Reliable Marker in Distinguishing Nephrogenic Adenoma From Prostatic Adenocarcinoma.
Screening of differentially expressed genes and identification of AMACR as a prognostic marker in prostate cancer.
Selection of aptamers for fluorescent detection of alpha-methylacyl-CoA racemase by single-bead SELEX.
Semen AMACR protein as a novel method for detecting prostate cancer.
Sensitivity of P504S/alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry for the detection of prostate carcinoma on stored needle biopsies.
Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk.
Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk: a replication study in an ethnically homogeneous population.
Sequence variation in alpha-methylacyl-CoA racemase and risk of early-onset and familial prostate cancer.
Serum levels of phytanic acid are associated with prostate cancer risk.
Sigmoid Colon Adenocarcinoma with Isolated Loss of PMS2 Presenting in a Patient with Synchronous Prostate Cancer with Intact MMR: Diagnosis and Analysis of the Family Pedigree.
Significant association of alpha-methylacyl-CoA racemase gene polymorphisms with susceptibility to prostate cancer: a meta-analysis.
Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology.
Sulforaphane Bioavailability and Chemopreventive Activity in Men Presenting for Biopsy of the Prostate Gland: A Randomized Controlled Trial.
Suppression of ?-methylacyl-coenzyme A racemase by miR200c inhibits prostate adenocarcinoma cell proliferation and migration.
T2E (TMPRSS2-ERG) fusion transcripts are associated with higher levels of AMACR mRNA and a subsequent prostate cancer diagnosis in patients with atypical small acinar proliferation.
The auxiliary diagnostic value of prostate-specific antigen and ?-methylacyl-CoA racemase in prostate cancer.
The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.
The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase.
The role of combined measurement of tissue mRNA levels of AMACR and survivin in the diagnosis and risk stratification of patients with suspected prostate cancer.
Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens.
Transcriptome analysis of human colon Caco-2 cells exposed to sulforaphane.
Use of p63/P504S monoclonal antibody cocktail in immunohistochemical staining of prostate tissue.
Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer.
Utility of ERG Versus AMACR Expression in Diagnosis of Minimal Adenocarcinoma of the Prostate in Needle Biopsy Tissue.
Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy.
Utility of racemase and other immunomarkers in the detection of adenocarcinoma in prostatic tissue damaged by high intensity focused ultrasound therapy.
Variants in the alpha-Methylacyl-CoA racemase gene and the association with advanced distal colorectal adenoma.
What's new in prostate cancer disease assessment in 2006?
[An update of biomarkers in prostate cancer tissue]
[Basal-luminal epithelial cell differentiation in prostate cancer is associated with epithelial-mesenchymal transition and epithelium migration in the mesenchyme].
[Detection of AMACR (P504S), P63 and 34betaE12 cocktail in the early diagnosis of prostate cancer]
[Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer].
[Evaluation of p63 and p504s markers for the diagnosis of prostate cancer]
[Histopathological features of prostate cancer]
[Immunohistochemical algorithms in prostate diagnostics : What's new?]
[Markers for diagnosis, prediction and prognosis of prostate cancer]
[P504S and 34betaE12 dual-staining of immunohistochemistry in the diagnosis of prostate cancer]
[Related biomarkers in the diagnosis of prostate cancer].
[Value of the antibody cocktail anti p63 + anti p504s for the diagnosis of prostatic cancer]
Prostatitis
Circulating Prostate Cells Found in Men with Benign Prostate Disease Are P504S Negative: Clinical Implications.
Refsum Disease
Peroxisomal disorders affecting phytanic acid alpha-oxidation: a review.
The influence of the branched-chain fatty acids pristanic acid and Refsum disease-associated phytanic acid on mitochondrial functions and calcium regulation of hippocampal neurons, astrocytes, and oligodendrocytes.
Rhabdomyolysis
Relapsing rhabdomyolysis due to peroxisomal alpha-methylacyl-coa racemase deficiency.
Sarcoma
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Seizures
Phytol is lethal for Amacr-deficient mice.
Sertoli Cell Tumor
Sertoli cell tumor of the testis, not otherwise specified, presenting extensive hemorrhage and overexpression of alpha-methylacyl-CoA racemase (AMACR/P504S).
Small Cell Lung Carcinoma
Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
Squamous Cell Carcinoma of Head and Neck
AMACR overexpression acts as a negative prognostic factor in oral squamous cell carcinoma.
Stomach Neoplasms
?-Methylacyl-CoA Racemase (AMACR) in Gastric Cancer: Correlation With Clinicopathologic Data and Disease-free Survival.
Alpha-Methylacyl-CoA Racemase Expression is Upregulated in Gastric Adenocarcinoma: A Study of 249 Cases.
Relationship between alpha-methylacyl-coenzyme A racemase expression and mucin phenotype in gastric cancer.
Thrombosis
?-Methylacyl-CoA racemase (AMACR) serves as a prognostic biomarker for the early recurrence/metastasis of HCC.
Thymoma
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Tremor
Tremor and deep white matter changes in alpha-methylacyl-CoA racemase deficiency.
Tuberculosis
A Continuous Assay for alpha-Methylacyl-CoA Racemase (AMACR) Using Circular Dichroism.
Alpha-methylacyl-CoA racemase from Mycobacterium tuberculosis. Mutational and structural characterization of the active site and the fold.
Crystallization and preliminary X-ray diffraction studies of an alpha-methylacyl-CoA racemase from Mycobacterium tuberculosis.
Preparation and characterization of the antibody recognizing AMACR inside its catalytic center.
The catalysis of the 1,1-proton transfer by alpha-methyl-acyl-CoA racemase is coupled to a movement of the fatty acyl moiety over a hydrophobic, methionine-rich surface.
Urinary Bladder Neoplasms
Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases.
Expression of alpha-methylacyl-CoA racemase correlates with histopathologic grading in noninvasive bladder cancer.
Vitamin K Deficiency
Fibroblast studies documenting a case of peroxisomal 2-methylacyl-CoA racemase deficiency: possible link between racemase deficiency and malabsorption and vitamin K deficiency.
Wilms Tumor
Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma.
Xanthomatosis, Cerebrotendinous
Mechanisms of disease: Inborn errors of bile acid synthesis.
Zellweger Syndrome
Mechanisms of disease: Inborn errors of bile acid synthesis.
Plasma analysis of di- and trihydroxycholestanoic acid diastereoisomers in peroxisomal alpha-methylacyl-CoA racemase deficiency.